



Journal of the British Thoracic Society

Impact Factor: 8.272

Editors-in-Chief

N Hart (UK)
G Jenkins (UK)
AR Smyth (UK)

Deputy Editors

N Kaminski (USA)
M Rosenfeld (USA)

Associate Editors

D Baldwin (UK)	J-L Pepin (France)
R Chambers (UK)	M Polkey (UK)
T Coleman (UK)	J Quint (UK)
GJ Criner (USA)	N Rahman (UK)
J Davies (UK)	K Robinson (USA)
A Floto (UK)	S Shaheen (UK)
M Griffiths (UK)	R Stevens (USA)
L Heaney (UK)	A Vonk Noordegraaf
N Hopkinson (UK)	(The Netherlands)
S Janes (UK)	C Wainwright (Australia)
B Kampman (UK)	T Wilkinson (UK)
B Mohlekesi (USA)	P Wolters (USA)

Statistical Editors

A Douiri (UK)
C Flach (UK)
C Jackson (UK)
S Stanojevic (USA)
R Szczesniak (USA)
B Wagner (USA)
Y Wang (UK)

Journal Club Editor

P Murphy (UK)

President, British Thoracic Society

Professor M Woodhead

Editorial Office

Thorax, BMA House, Tavistock Square,
London WC1H 9JR, UK
T: +44 (0)20 7383 6373
E: thorax@bmj.com

Twitter: @ThoraxBMJ

ISSN: 0040-6376 (print)
ISSN: 1468-3296 (online)

Disclaimer: Thorax is owned and published by the British Thoracic Society and BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association. The owners grant editorial freedom to the Editor of Thorax.

Thorax follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

Thorax is intended for medical professionals and is provided without warranty, express or implied. Statements in the Journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group Ltd, the British Thoracic Society or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group Ltd shall not be liable for any loss, injury or damage resulting from the use of Thorax or any information in it whether based on contract, tort or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2018 BMJ Publishing Group Ltd and the British Thoracic Society. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior permission of Thorax.

Thorax is published by BMJ Publishing Group Ltd, typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Thorax (ISSN No: 0040-6376) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431. POSTMASTER: send address changes to Thorax, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Section 1: Introduction

- i3 Aim of the guideline
- i3 Intended users of the guideline and target patient populations
- i3 Areas covered by the guideline
- i3 Areas not covered by the guideline
- i3 Limitations of the guideline
- i3 Members of the guideline development group
- i3 Representation

Section 2: Methodology of guideline production

- i4 Establishment of guideline development group
- i4 Methodology
- i4 Summary of key questions and literature search
- i4 Appraisal of the evidence
- i5 Planned review and updating of the guideline
- i5 Declarations of interest
- i5 Stakeholders

Section 3: Clinical features which predict the presence of mesothelioma

- i5 Symptoms
- i6 Evidence statements
- i6 Recommendations

Section 4: Staging systems

- i7 Evidence statements
- i7 Recommendations

Section 5: Imaging modalities for diagnosing and staging

- i8 Evidence on diagnostic imaging
- i8 Evidence on staging
- i9 Evidence statements
- i9 Recommendations

Section 6: Pathological diagnosis

- i10 Summary of individual immunohistochemistry data
- i10 Additional techniques
- i10 Diagnosis in cytology
- i10 Evidence statements
- i11 Recommendations
- i11 Good practice points

Section 7: Use of biomarkers

- i11 Evidence on diagnostic markers
- i11 Markers for disease monitoring and assessment of progression
- i12 Outcome prediction
- i12 Biomarkers for screening
- i12 Evidence statements
- i12 Recommendations

Section 8: Factors determining prognosis and timing of treatment

- i13 Evidence from very large studies
- i13 Findings from the National Lung Cancer Audit
- i13 The EORTC prognostic score
- i13 CALGB prognostic groups
- i13 The neutrophil-to-lymphocyte ratio
- i13 The modified Glasgow prognostic score
- i13 Prognostic model using decision tree analysis
- i14 The LENT score
- i14 Symptoms
- i14 Evidence statements
- i14 Recommendations

Section 9: Fluid management

- i15 Evidence statements
- i15 Recommendations

Section 10: The role of surgery

- i15 Evidence review
- i15 Pleurectomy
- i15 Extended pleurectomy decortication and Extra-pleural pneumonectomy
- i16 Evidence statements
- i16 Recommendations

Section 11: Systemic anti-cancer treatment

- i16 Evidence
- i16 Evidence on first-line systemic therapy
- i17 Second-line systemic treatments in MPM
- i18 Evidence statements
- i18 Recommendations
- i18 Good practice points

Section 12: Radiotherapy

- i18 Prophylactic radiotherapy to procedure tracts
- i18 Evidence review
- i19 Evidence statements
- i19 Recommendations
- i19 Radiotherapy as part of multimodality treatment
- i19 Evidence review
- i19 Evidence statements

MORE CONTENTS ►

This article has been chosen by the Editors to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://authors.bmj.com/open-access/>

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics <http://publicationethics.org/>



- i19** Recommendations
- i20** Radiotherapy for symptom palliation
- i20** Evidence review
- i20** Evidence statements
- i20** Recommendations

Section 13: Symptom control

- i20** Evidence statement
 - i20** Good practice point
-

Section 14: Care and management

- i21** Care in multi-disciplinary teams
 - i21** Evidence statement
 - i21** Recommendations
 - i21** Good practice point
 - i21** Information needs of patients
 - i21** Evidence review
 - i21** Compensation
 - i22** Evidence statement
 - i22** Recommendations
 - i22** Follow-up strategies
 - i22** Evidence statement
 - i23** Recommendations
 - i23** Good practice point
-

Tables

- i4** Table 1: SIGN levels of evidence
- i5** Table 2: SIGN grades of recommendation
- i6** Table 3: Symptoms at initial presentation in 90 evaluable cases of malignant pleural mesothelioma
- i6** Table 4: NICE NG 12: Referral criteria for suspected malignant pleural mesothelioma
- i7** Table 5: 8th edition AJCC/UICC staging for malignant pleural mesothelioma
- i7** Table 6: TNM Stage Groupings Proposed for the Eighth Edition of MPM Staging System Relative to Those Used in the Seventh Edition

- i8** Table 7: Diagnostic accuracy of different imaging modalities for diagnostic vs benign pleural disease
 - i9** Table 8: Showing the sensitivity and specificity of CT, MRI and PET-CT in mesothelioma staging
 - i9** Table 9: Mesothelioma subtypes
 - i10** Table 10: Summary of IHC markers
 - i11** Table 11: Summary of sensitivities and specificities for SMRP and Osteopontin
 - i12** Table 12: Summary sensitivities and specificities for Fibulin-3
 - i13** Table 13: Brim decision tree classification
 - i14** Table 14: Summary of LENT score and median survival
 - i16** Table 15: Randomised phase III trials in first-line treatment of MPM
 - i19** Table 16: Summary of trials comparing prophylactic radiotherapy to procedure tracts to no radiotherapy
 - i20** Table 17: Summary of studies exploring localised hemithorax irradiation
 - i20** Table 18: Summary of current cancer related symptom management guidelines in relation to common symptoms seen in MPM
-

Figures

- i7** Figure 1: Overall survival according to best stage (proposed eighth edition)
-

Appendices

- i28** Appendix 1: List of guideline group members
 - i29** Appendix 2: Prognostic scores
-

Online Appendices

- Online Appendix 1: Literature search strategy
- Online Appendix 2: Evidence tables